Lilly to Invest an Additional $4.5B Across Two Indiana Sites

Eli Lilly and Company is investing an additional $4.5 billion across two of its three Lebanon sites—bringing the company’s total Indiana capital expansion commitments since 2020 to more than $21 billion. The investment will incorporate new process designs and technologies at Lilly Lebanon API, one of the company’s future active pharmaceutical ingredient sites, as well as Lilly Lebanon Advanced Therapies, its first dedicated genetic medicine manufacturing facility, which opened last week.

Lebanon, Indiana, is the cornerstone of Lilly’s domestic manufacturing buildout. In 2024, Lilly announced plans to make both Zepbound (tirzepatide) and Mounjaro (tirzepatide), the most prescribed injectable medications for weight management and type 2 diabetes respectively, at its Lebanon API site. Today’s investment expands that commitment further, including planned production of Foundayo (orforglipron), Lilly’s first FDA-approved, once-daily pill for weight loss that can be taken without food or water restrictions, and retatrutide, an investigational triple hormone receptor agonist in late-stage development for obesity and cardiometabolic disease.

“Lilly’s legacy of firsts in Indiana continues today—and the best measure of that legacy is what we do next,” said David A. Ricks, Lilly chair and CEO. “From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future—we are building the world’s most advanced plants to make them. When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history, a commitment we chose to build here, at home.”

Related News

In 2024, Eli Lilly and Co. invested $4.5 billion to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.